Logo image
Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - An unrevealed role in downregulation of Th17 cells
期刊文章   同儕審查

Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - An unrevealed role in downregulation of Th17 cells

Yen-Ling Wang, Feng-Cheng Chou, Shyi-Jou Chen, Shih-Hua Lin, Deh-Ming ChangHuey-Kang Sytwu
Journal of Autoimmunity, 卷.37(3), 頁碼.160-170
11/2011
PMID: 21689905

摘要

Experimental autoimmune encephalomyelitis NOD mice Pre-ligand assembly domain Th17 Immunology and Allergy Immunology
The pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors mediates specific ligand-independent receptor assembly and subsequent signaling. However, the physiological role of PLAD in the regulation of TNFR-mediated immune responses in autoimmunity is still unclear. By using the recombinant PLAD.Fc protein to block TNFR1 assembly, we demonstrated that PLAD.Fc treatment significantly reduced the TNFR1-driving proinflammatory cytokines and protected NOD mice from diabetes. Strikingly, Th17 differentiation was significantly inhibited in PLAD.Fc-treated NOD and TNFR1-deficient mice, indicating a TNFR1-dependent Th17 development. PLAD.Fc-modulated effects on DCs, in terms of the downregulation of Th17-inducing cytokines, IL-6 and TGF-β, explained the potential mechanism for Th17 suppression. Finally, we provided an additional result that PLAD.Fc administration diminished the infiltration of Th17 cells in the central nervous system and ameliorated the experimental autoimmune encephalomyelitis in mice. Collectively, these data demonstrated that targeting PLAD of TNFR1 provides protection from autoimmune diseases through the downregulation of Th17 and suggested a therapeutic potential of PLAD-modulation in TNF-involved inflammatory diseases. © 2011 Elsevier Ltd.

相關連結

指標

1 檢視次數

詳細資料

Logo image